BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

751 related articles for article (PubMed ID: 35722420)

  • 1. Identification of metabolism-related long non-coding RNA (lncRNA) signature predicts prognosis and immune infiltrates in hepatocellular carcinoma.
    Wang X; Qian J; Yao N; Pocha C; Kang KJ; Angelico R; Zhu G
    Ann Transl Med; 2022 May; 10(10):595. PubMed ID: 35722420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Cuproptosis-Related LncRNA Risk Model for Predicting Prognosis and Immunotherapeutic Efficacy in Patients with Hepatocellular Carcinoma.
    Wang S; Bai H; Fei S; Miao B
    Biochem Genet; 2023 Oct; ():. PubMed ID: 37898914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a cuproptosis and copper metabolism gene-related lncRNAs prognostic signature associated with clinical and immunological characteristics of hepatocellular carcinoma.
    Yuan W; Xiao JH; Zhang JS; Mao BL; Wang PZ; Wang BL
    Front Oncol; 2023; 13():1153353. PubMed ID: 37056336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a five-long non-coding RNA signature to improve the prognosis prediction for patients with hepatocellular carcinoma.
    Zhao QJ; Zhang J; Xu L; Liu FF
    World J Gastroenterol; 2018 Aug; 24(30):3426-3439. PubMed ID: 30122881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The development and validation of a novel senescence-related long-chain non-coding RNA (lncRNA) signature that predicts prognosis and the tumor microenvironment of patients with hepatocellular carcinoma.
    Huang E; Ma T; Zhou J; Ma N; Yang W; Liu C; Hou Z; Chen S; de Castria TB; Zeng B; Zong Z; Zhou T
    Ann Transl Med; 2022 Jul; 10(14):766. PubMed ID: 35965795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic analysis of
    Li D; Fan X; Zuo L; Wu X; Wu Y; Zhang Y; Zou F; Sun Z; Zhang W
    Ann Transl Med; 2022 Dec; 10(24):1356. PubMed ID: 36660710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma.
    Fu Y; Wei X; Han Q; Le J; Ma Y; Lin X; Xu Y; Liu N; Wang X; Kong X; Gu J; Tong Y; Wu H
    BMC Cancer; 2021 Oct; 21(1):1165. PubMed ID: 34717566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel signature incorporating lipid metabolism- and immune-related genes to predict the prognosis and immune landscape in hepatocellular carcinoma.
    Yang T; Luo Y; Liu J; Liu F; Ma Z; Liu G; Li H; Wen J; Chen C; Zeng X
    Front Oncol; 2023; 13():1182434. PubMed ID: 37346073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A New Prognostic Strategy Based on four DNA Repair-Associated lncRNAs for Hepatocellular Carcinoma.
    Zeng H; Liu C; Zhou X; Liu L
    Comb Chem High Throughput Screen; 2022; 25(5):906-918. PubMed ID: 33653241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Construction of an Immune-Related Six-lncRNA Signature to Predict the Outcomes, Immune Cell Infiltration, and Immunotherapy Response in Patients With Hepatocellular Carcinoma.
    Zhou P; Lu Y; Zhang Y; Wang L
    Front Oncol; 2021; 11():661758. PubMed ID: 34277410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Six-long non-coding RNA signature predicts recurrence-free survival in hepatocellular carcinoma.
    Gu JX; Zhang X; Miao RC; Xiang XH; Fu YN; Zhang JY; Liu C; Qu K
    World J Gastroenterol; 2019 Jan; 25(2):220-232. PubMed ID: 30670911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identifying a Hypoxia-Related Long Non-Coding RNAs Signature to Improve the Prediction of Prognosis and Immunotherapy Response in Hepatocellular Carcinoma.
    Tang P; Qu W; Wang T; Liu M; Wu D; Tan L; Zhou H
    Front Genet; 2021; 12():785185. PubMed ID: 34917132
    [No Abstract]   [Full Text] [Related]  

  • 13. A novel cuproptosis-related lncRNA signature predicts the prognosis and immunotherapy for hepatocellular carcinoma.
    Liu Y; Jiang J
    Cancer Biomark; 2023; 37(1):13-26. PubMed ID: 37005878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of an Epithelial-Mesenchymal Transition-Related Long Non-coding RNA Prognostic Signature to Determine the Prognosis and Drug Treatment of Hepatocellular Carcinoma Patients.
    Huang S; Li D; Zhuang L; Zhang J; Wu J
    Front Med (Lausanne); 2022; 9():850343. PubMed ID: 35685422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A somatic mutation-derived LncRNA signatures of genomic instability predicts the prognosis and tumor microenvironment immune characters in hepatocellular carcinoma.
    Jin C; Zhao JS; Huang XQ; Yang XZ; Niu FY; Lin JR; Ma L; Shi YX; Li XS; Jiang P; Gao S; Li F; Song Y
    Hepatol Int; 2022 Oct; 16(5):1220-1233. PubMed ID: 35947245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel five-gene signature predicts overall survival of patients with hepatocellular carcinoma.
    Wang Z; Pan L; Guo D; Luo X; Tang J; Yang W; Zhang Y; Luo A; Gu Y; Pan Y
    Cancer Med; 2021 Jun; 10(11):3808-3821. PubMed ID: 33934539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Construction of a Necroptosis-Associated Long Non-Coding RNA Signature to Predict Prognosis and Immune Response in Hepatocellular Carcinoma.
    Wang W; Ye Y; Zhang X; Ye X; Liu C; Bao L
    Front Mol Biosci; 2022; 9():937979. PubMed ID: 35911976
    [No Abstract]   [Full Text] [Related]  

  • 18. Ferroptosis-related long non-coding RNA signature predicts the prognosis of hepatocellular carcinoma.
    Yang X; Mei M; Yang J; Guo J; Du F; Liu S
    Aging (Albany NY); 2022 May; 14(9):4069-4084. PubMed ID: 35550563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and Validation of a Prognostic Signature Associated With Tumor Microenvironment Based on Autophagy-Related lncRNA Analysis in Hepatocellular Carcinoma.
    Deng Y; Zhang F; Sun ZG; Wang S
    Front Med (Lausanne); 2021; 8():762570. PubMed ID: 34970559
    [No Abstract]   [Full Text] [Related]  

  • 20. Novel chemokine related LncRNA signature correlates with the prognosis, immune landscape, and therapeutic sensitivity of esophageal squamous cell cancer.
    Zhang Z; Wang J; Han W; Zhao L
    BMC Gastroenterol; 2023 Apr; 23(1):132. PubMed ID: 37081402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.